On February 17, 2026, ICAHN CARL C disclosed a buy of Icahn Enterprises (NASDAQ:IEP) . According to a recent SEC filing , ICAHN CARL C increased its stake in Icahn Enterprises by 30,467,595 shares during the fourth quarter. The estimated value of this purchase was $245.63 million, calculated using the average closing price over the quarter. As a result, the fund’s quarter-end position in IEP rose ...
On February 17, 2026, ICAHN CARL C disclosed a buy of Icahn Enterprises (NASDAQ:IEP) . According to a recent SEC filing , ICAHN CARL C increased its stake in Icahn Enterprises by 30,467,595 shares during the fourth quarter. The estimated value of this purchase was $245.63 million, calculated using the average closing price over the quarter. As a result, the fund’s quarter-end position in IEP rose to 549,400,539 shares, with the total value of the stake decreasing by $221.44 million compared to the previous filing. Icahn Enterprises is a diversified conglomerate with significant operations across multiple sectors, including energy, automotive, and real estate. Continue reading
Nvidia (NVDA) reported its Q4 earnings on Feb. 25 after the bell. Despite the earnings smasher, the stock is trading 5.6% lower at the time of writing, Thursday, Feb. 26, according to Yahoo Finance. The stock's crash after earnings, no matter how strong the report, has seemingly become the norm for ...
Nvidia (NVDA) reported its Q4 earnings on Feb. 25 after the bell. Despite the earnings smasher, the stock is trading 5.6% lower at the time of writing, Thursday, Feb. 26, according to Yahoo Finance. The stock's crash after earnings, no matter how strong the report, has seemingly become the norm for ...
By Rocky Swift TOKYO, Feb 27 (Reuters) - Dour sentiment persisted in the Asian trading day on Friday as concerns about technology company valuations weighed on shares and Middle East tensions kept
By Rocky Swift TOKYO, Feb 27 (Reuters) - Dour sentiment persisted in the Asian trading day on Friday as concerns about technology company valuations weighed on shares and Middle East tensions kept
Retail sales are still rising, but record household savings, stepped-up gold buying and reined-in income expectations suggest the population of the world’s second largest economy is now prioritizing security over splurges — with consequences for global brands and investors.
Retail sales are still rising, but record household savings, stepped-up gold buying and reined-in income expectations suggest the population of the world’s second largest economy is now prioritizing security over splurges — with consequences for global brands and investors.
Earnings Call Insights: Castle Biosciences (CSTL) Q4 2025 Management View CEO Derek Maetzold highlighted a strong finish to 2025, citing "continued momentum across our core revenue drivers, disciplined execution and the dedication of our employees." He reported fourth quarter revenue of $87.0 million and full-year revenue of $344.2 million. Excluding DecisionDx-SCC and IDgenetix, revenue growth fo...
Earnings Call Insights: Castle Biosciences (CSTL) Q4 2025 Management View CEO Derek Maetzold highlighted a strong finish to 2025, citing "continued momentum across our core revenue drivers, disciplined execution and the dedication of our employees." He reported fourth quarter revenue of $87.0 million and full-year revenue of $344.2 million. Excluding DecisionDx-SCC and IDgenetix, revenue growth for the year reached approximately 34%. Total test report volume from core revenue drivers increased 37% to 105,053, with TissueCypher test report volume growing 86% over 2024. Maetzold emphasized the acquisition of Previse, a collaboration and license agreement with SciBase, and the launch of the AdvanceAD-Tx test as key milestones. He noted, "Early results [from AdvanceAD-Tx] have exceeded our high expectations," with more than half of the initial 150 dermatological accounts ordering tests in the first 5 weeks of clinical availability. DecisionDx-Melanoma surpassed 230,000 test orders since launch, with 1,795 new clinicians ordering in 2025. The company reached approximately 31% patient penetration for DecisionDx-Melanoma exiting 2025. Maetzold stated, "We continue to expect M&A to play a role," with a focus on tests near market, reimbursement, and those fitting within existing sales teams and customer verticals. CFO Frank Stokes stated, "In the fourth quarter of 2025, we delivered total revenue of $87 million, resulting in $344.2 million for the full year 2025, exceeding our guidance range." He added, "For 2026, we anticipate generating total revenue of $340 million to $350 million." Outlook Management guided total revenue for 2026 to $340 million to $350 million, with growth in the mid- to high teens over 2025 on a comparable basis excluding DecisionDx-SCC and IDgenetix. Revenue growth is expected to be driven primarily by continued TissueCypher momentum. AdvanceAD-Tx is expected to have immaterial revenue contribution in 2026, with material contribution anticipated in 20...
Earnings Call Insights: Cytek Biosciences (CTKB) Q4 2025 Management View Wenbin Jiang, President, CEO & Chairman of the Board, stated that "Fourth quarter revenue in 2025 reached $62.1 million, representing a year-over-year increase of 8% compared to the same period in 2024 and notably the highest revenue historically achieved in a quarter at Cytek." Growth was highlighted in U.S. stabilization, E...
Earnings Call Insights: Cytek Biosciences (CTKB) Q4 2025 Management View Wenbin Jiang, President, CEO & Chairman of the Board, stated that "Fourth quarter revenue in 2025 reached $62.1 million, representing a year-over-year increase of 8% compared to the same period in 2024 and notably the highest revenue historically achieved in a quarter at Cytek." Growth was highlighted in U.S. stabilization, EU turnaround, sustained APAC strength, and the expansion of recurring revenue. Jiang reported that "in the fourth quarter, EMEA and APAC both posted double-digit year-over-year percentage revenue increases with solid gains across instruments, reagents and service." Jiang emphasized, "We have also been very pleased with the performance of our new Cytek Aurora Evo system...driving 21% unit growth in the combined Aurora category in the fourth quarter versus Q4 of 2024." He mentioned the Muse Micro System was awarded the 2025 Biotech Breakthrough Award for Drug Discovery Solution of the Year and noted recurring revenue represented 34% of total revenue in 2025 with 21% year-over-year growth. The company established a new manufacturing facility in Singapore, which began generating revenue in under 100 days, strengthening supply chain resilience. William McCombe, Chief Financial Officer, stated, "Fourth quarter revenue was $62.1 million, up 8% year-over-year. Growth was driven by strong global performance in service and reagents, continued momentum in instrument demand across Asia Pacific and a rebound in EMEA instrument demand among academic and government customers." McCombe attributed product revenue increases to "double-digit gains in APAC and EMEA as well as a low single-digit gain in the U.S.," and highlighted a "25% growth in Q4 versus the prior year quarter" in service revenue. Outlook The company is initiating 2026 revenue guidance of $205 million to $212 million, assuming constant currency exchange rates and no significant change in tariffs. McCombe explained, "This guid...
Taiwanese leader William Lai Ching-te’s rare reference to “mainland China” signals caution ahead of a highly anticipated Xi-Trump summit, according to analysts who say it is premature to declare a shift in his cross-strait policy. Addressing a group of Taiwanese businesspeople operating on the mainland on Tuesday, Lai used the term “mainland China” multiple times, contrasting with his frequent use...
Taiwanese leader William Lai Ching-te’s rare reference to “mainland China” signals caution ahead of a highly anticipated Xi-Trump summit, according to analysts who say it is premature to declare a shift in his cross-strait policy. Addressing a group of Taiwanese businesspeople operating on the mainland on Tuesday, Lai used the term “mainland China” multiple times, contrasting with his frequent use of “China” in major speeches since his 2024 inauguration as the self-ruled island’s leader. During...